Effi Parenterals Faces Blacklisting in Chhattisgarh After Failing Drug Quality Tests

In a move to uphold stringent quality control standards, the Chhattisgarh Medical Services Corporation Limited (CGMSCL) has issued a blacklisting show-cause notice to M/s. Effi Parenterals. This action stems from a failure of quality tests conducted on Albendazole tablets IP 400 mg (Drug Code – D12), supplied by the company. The CG health department mandates that all drug batches are tested in NABL-accredited labs prior to distribution to hospitals, ensuring that only medications meeting quality standards are provided. The specific batches in question, PGT25451, PGT25450, PGT25480, and PGT25229, failed quality assessments at the State Drug Testing and Research Laboratory, Raipur. The firm has been directed to withdraw all rejected batches from the drug warehouses.